Jefferies Remains a Buy on Samvardhana Motherson International Limited (MOTHERSON)
Confident Investing Starts Here:
Mangal covers the Consumer Cyclical sector, focusing on stocks such as Bajaj Auto Limited, Hero Motocorp Limited, and TVS Motor Company Limited. According to TipRanks, Mangal has an average return of 0.1% and a 43.33% success rate on recommended stocks.
In addition to Jefferies, Samvardhana Motherson International Limited also received a Buy from CLSA's Basudeb Banerjee in a report issued on May 30. However, yesterday, Investec maintained a Hold rating on Samvardhana Motherson International Limited (NSE: MOTHERSON).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
National Bank Keeps Their Buy Rating on Kinross Gold (KGC)
National Bank analyst Shane Nagle maintained a Buy rating on Kinross Gold today and set a price target of C$28.00. The company's shares closed today at $16.21. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nagle covers the Basic Materials sector, focusing on stocks such as Kinross Gold, Barrick Mining, and Hudbay Minerals. According to TipRanks, Nagle has an average return of 18.9% and a 66.80% success rate on recommended stocks. In addition to National Bank, Kinross Gold also received a Buy from CIBC's Anita Soni in a report issued today. However, on July 21, RBC Capital maintained a Hold rating on Kinross Gold (NYSE: KGC). The company has a one-year high of $16.52 and a one-year low of $7.84. Currently, Kinross Gold has an average volume of 20.13M. Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KGC in relation to earlier this year.
Business Insider
an hour ago
- Business Insider
Why Airbnb (ABNB) is a Hot Buy Ahead of Next Week's Earnings
Airbnb (ABNB) may be gearing up for a breakout moment. Despite a modest year-to-date return of just over 4%, the company is showing signs of accelerating growth and significantly expanding its total addressable market. From a redesigned app to a bold strategy shift toward becoming the 'Amazon of Services,' Airbnb is operating as though it could soon surprise the market. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I'm stoutly Bullish on Airbnb stock ahead of next week's earnings report, expected to hit the market after market close on Wednesday, August 6th. Ultimately, I see a stock driven by margin expansion, new verticals, and a recovering travel market that is set to unlock fresh revenue opportunities. Airbnb's Q1 Earnings Beat Expectations Taking a step back, on May 1, Airbnb posted solid Q1 2025 results, delivering an EPS of $0.24 versus the Street's expectation of $0.23. Revenue climbed 6% year-over-year to $2.27 billion, slightly above the $2.26 billion consensus estimate. Gross booking value rose 7% to $24.5 billion, supported by 143.1 million nights and experiences booked, up 8% from the year-ago period. However, the company issued a more muted Q2 revenue outlook, guiding for $2.99 billion to $3.05 billion, slightly under the $3.03 billion consensus at the midpoint. Despite this, Airbnb reaffirmed its full-year adjusted EBITDA margin guidance of at least 34.5%, signaling confidence in its cost management and pricing power. Since the May earnings release, Airbnb stock has gained 9.2%, underperforming the S&P 500's 12% rise. So far this year, Airbnb is up just 4.13% versus the index's 8.32% gain, suggesting plenty of room for a catch-up rally. The stock's most recent price action indicates fairly strong bearish sentiment, which has pushed the stock lower for the past three days in a row. What to Watch Out for on August 6th Airbnb market analysts have been slowly raising their forecasts leading into next week's performance figures: consensus EPS estimates have climbed from $0.88 to $0.94 since the last earnings report, reflecting growing optimism. I believe the company's EBITDA margin guidance remains conservative and expect upside in both profitability and topline performance. Key catalysts include improving attach rates in Airbnb's Experiences and Services segments, as well as a broader rebound in global travel. Notably, — and in both cases, the stock traded higher the following day. Redesigned App Signals Strategic Pivot Airbnb's newly redesigned app, launched in May this year, introduces distinct tabs for Homes, Experiences, and Services, a signal of the company's ambition to become more than just a lodging marketplace. In a recent Bloomberg interview, CEO Brian Chesky shared that Airbnb wants to emulate Amazon in the Services sector. With two-thirds of U.S. jobs currently reliant on this particular part of the U.S. economy, this pivot dramatically expands the company's total addressable market. According to the ambitious CEO, his goal is to build a full-scale services platform where users can book not just homes, but also experiences, local services, and more. I expect this initiative alone could eventually drive an incremental $10 billion in annual bookings. Airbnb's Valuation is High, But Justified Yes, Airbnb trades at a premium: its trailing 12-month P/E ratio stands at 35.8, compared to a sector median of just 19.6. But I believe this premium is justified by the company's midterm revenue growth potential and expanding margins. Consensus projects around 9.5% midterm revenue growth, which I view as conservative given accelerating trends in its core markets and the Services vertical. My own valuation work, based on 12 models including EV/EBITDA, P/E, and 10-year DCF with an EBITDA exit, suggests a fair value of $153.90, implying over 12% upside from current levels. What is the 12-Month Price Target for Airbnb? According to TipRanks, Airbnb holds a Hold consensus rating, based on 28 recent analyst reviews, which includes eight Buys, 14 Holds, and six Sells. ABNB's average stock price target is $135.71, implying ~2.5% upside over the next twelve months. That said, July saw a string of price target hikes and positive analyst actions, reflecting growing confidence ahead of earnings. Bernstein SocGen reiterated its Outperform rating and $165 target, commenting that Airbnb is currently going it alone in Services and Experiences, sourcing both supply and demand through its own brand marketing. Bernstein noted that the company could accelerate growth by partnering with established platforms for services it doesn't yet offer—like airport transfers, car rentals, or gear rentals—and by expanding visibility, such as bidding on high-intent search terms like 'Experiences Paris.' While they expect Airbnb to stick with its current strategy for now, these tactics could drive broader adoption and usage. In addition, Deutsche Bank maintained its $125 price target with a Hold rating, while Swiss bank UBS lifted its target to $156 from $137 with a Neutral rating. Airbnb is Poised to Surprise Airbnb isn't just another travel stock. It's evolving into a powerful digital services platform, with high margins, ample cash flow, and a visionary CEO charting bold new territory. With profitability gaining strength, vertical expansion underway, and a potentially transformative strategy shift in motion, I believe Airbnb is positioned for acceleration in the coming quarters. For investors seeking growth in a dynamic, post-pandemic travel-tech landscape, Airbnb may be worth buying in advance of next week's earnings news.
Business Insider
2 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
